Like the previous year, 2021 is expected to be dominated by the coronavirus pandemic. Apart from the difficulties it has imposed on the healthcare system, it has made India realise the importance of biomedical resources. It has pushed India to optimise the latent capabilities which the country possesses, across the public and private sector to promote indigenous development and manufacturing.
2020 saw many innovative solutions entering the market within the diagnostic space particularly for COVID-19 testing. A majority of them came from the academic sector, after receiving timely regulatory approvals and commercialisation.
Although India worked relentlessly towards developing innovative testing solutions for COVID-19 throughout last year, the timely detection of a number of other infectious diseases got sidelined. A recent example is the rise of a rare fungal infection mucormycosis.
In India, the range and burden of infectious diseases are enormous such as tuberculosis, malaria, filariasis, leprosy, HIV infection, typhoid, hepatitis etc. In fact, inadequate containment of the vector has resulted in recurrent outbreaks of dengue fever and reemergence of chikungunya virus disease and typhus fever.
For instance, India is home to approximately 2.8 million tuberculosis patients, making it the largest number in a single country. On the other hand, more than a decade after India eliminated leprosy, the disease continues to linger on. Adding on, India’s malaria surveillance system ranks among the worst in the world according to the World Health Organization (WHO). According to a study published in The Lancet in 2020, diarrheal diseases, tuberculosis and lower respiratory infections were among the leading causes of deaths in India in 2019.
Thus, after witnessing a range of novel diagnostic tests stepping into the market for rapid detection of COVID-19, India should lay focus on developing and commercializing similar point-of-care tests for other infectious diseases too, for their timely detection and subsequent elimination. If India can develop more than 20 different diagnostic tests or devices in a single year against COVID-19, many more such innovations can be brought out to effectively detect other infections looming in our country.
Translating ideas in lab
Amidst the ongoing pandemic, the need for devices that can rapidly detect and diagnose infectious bugs is evident within our scientific community. Resultantly, a number of researchers are finding out numerous ways to develop novel, inexpensive and easy-to-use devices to combat these diseases.
A recent example comes from the Indian Institute of Technology, Delhi (IIT-D) where a group of researchers has developed a handheld Surface Enhanced Raman Spectroscopy (SERS) based platform for early diagnosis of dengue virus. It gives dengue test results within one hour. The handheld device has been successfully tested on the clinical blood samples collected from hundreds of individuals in collaboration with the National Institute of Malaria Research (NIMR), New Delhi.
The detection and distinction of human immunodeficiency virus (HIV-1) was also carried out in collaboration with the National AIDS Research Institute (NARI), Pune through the handheld SERS based platform. It gives HIV-1 test results also within an hour. This research work has been funded by IMPRINT India programme of the Ministry of Education with Gurugram-based New Age Instruments and Materials as the industry partner.
“Dengue is a serious global health concern with a large population around the world facing the risk of getting infected. Early diagnosis of dengue is the key to prevent deterioration of a patient’s health. However, conventional diagnostic tools like nucleic acid detection using Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a time taking process and it also requires expensive equipment and reagents for the diagnosis of dengue. Our ultrasensitive and handy device has a wide range of applications in the early-stage on-site detection of viral diseases and can produce the final report of investigation within an hour”, says Dr J P Singh, Professor, Department of Physics, Indian Institute of Technology, Delhi.
Keeping a focus on rapid detection of tuberculosis (TB), engineers at the Indian Institute of Science (IISc) in Bengaluru have designed a low-cost paper-and-plastic device that can detect the presence of TB DNA in liquid samples. An untrained user can perform a TB test by simply adding liquid samples to the paper reaction zones and placing the device in an incubator for 60-80 minutes. The results of the test are read using a cell phone camera installed within a small plastic box. The material cost of fabricating the device is only Rs 61 and the cost of reagents per reaction zone is Rs 41.
“TB is the deadliest infectious disease today and India has the largest number of TB-related deaths among all countries in the world. Through our device, we have tried to address the challenges of affordability, accessibility, and user-friendliness. The technology is called Fluorescent Isothermal Paper-and-Plastic Nucleic Acid Amplification Test (FLIPP-NAAT). A pilot clinical trial done in collaboration with Christian Medical College (CMC) Vellore has achieved 100 per cent sensitivity for the detection of TB. Besides its application for the diagnosis of TB, it could be modified to detect other diseases as well”, says Dr. Bhushan Toley, Assistant Professor, Department of Chemical Engineering, Indian Institute of Science, Bengaluru.
Continue reading your story on the app
Continue reading your story in the magazine
“R&D outsourcing has become a ‘must have' than ‘good-to have' strategy”
Aragen Life Sciences (formerly GVK BIO), a leading contract research and development organisation headquartered in Hyderabad, is marking its transition to a new brand identity in its 20th year. Established in 2001, the company is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms with new investments and collaborations. In conversation with BioSpectrum, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, Hyderabad reveals more about the company’s recent rebranding and growth plans. Edited excerpts;
Premas Biotech to commercialise VLP vaccine tech against Delta variant
Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation of its virus-like-particle COVID-19 vaccine technology.
SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future
The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!
Merck launches Pergoveris Pen for fertility treatment in India
Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.
Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray
Mumbai-based Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corporation
CEPI prioritises Rift Valley fever vax
Sep 01, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has signed an implementing partner agreement with Integrum Scientific (US) as part of its ongoing efforts to combat Rift Valley fever (RVF)—one of its priority diseases with epidemic potential.
3D printing moulds healthcare innovations
Pharmaceuticals, bio-medicine, aviation, and automobiles industries have rapidly adopted 3D printing over the years, worldwide, to develop new solutions and prototypes. It is also helping many industries, healthcare, in particular, increase productivity. Despite all its advantages, 3D printing technology is currently posing a number of challenges in the market such as initial costs, limitation to the metals and plastics used for 3D printing, lack of policy standardisation, etc.
Mynvax Offers ‘Warm Vaccine' For COVID-19
Biotech startup Mynvax, incubated at the Indian Institute of Science (IISc) in Bengaluru, has developed heat-tolerant COVID-19 vaccine formulations.
How Tech Innovations Impact Cardiac Care
Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.
Zika Is the Next Front in the Mosquito Wars
Based on damage from malaria and dengue, the spread of Zika will prove costly.
जीवित मलेरिया परजीवी से निर्मित टीके की सफलता
हर वर्ष मलेरिया से लगभग चार लाख लोगों की मौत होती है। दवाइयों तथा कीटनाशक युक्त मच्छरदानी वगैरह से मलेरिया पर नियंत्रण में मदद मिली है लेकिन टीका मलेरिया नियंत्रण में मील का पत्थर साबित हो सकता है। मलेरिया के एक प्रायोगिक टीके के शुरुआती चरण में आशाजनक परिणाम मिले हैं।
लार्वा मारने के लिए तैयार किया 'ड्रोनास्त्र'
मुंबई में मलेरिया के बढ़ते मामलों पर रोक के लिए BMC की पहल
What You Should Know About Mosquitoes
Not all mosquitoes are created equal, say Shüné Oliver and Jaishree Raman of the National Institute for Communicable Diseases of South Africa. However, people should be sure to protect themselves when visiting regions known for mosquito-transmitted diseases.
Mosquito fest ‘could bring malaria to UK'
FEARS AMID 20% SURGE IN INSECTS
बचें मानसून के रोगों से
आमतौर पर मानसून को आशिकाना मौसम माना जाता है, किंतु जरा बच के रहिएगा इस मौसम में। नहीं तो मौसम का आशिकाना अंदाज सेहत पर भारी पड़ सकता है।
27 से अधिक टीमें कर रही हैं ब्लाक स्तर तक स्प्रे:उपायुक्त
डेंगू से बचाव के लिए प्रशासन सक्रिय
JANUARY 1-15, 1995 | DISEASE RESURGENCE - THE MICROBES STRIKE BACK
Diseases that were cheerfully believed to have been eradicated are inexplicably cropping up again in India
New malaria vaccine shows promise in trial
A potential new malaria vaccine has proved highly effective in a trial in babies in Africa, pointing to it one day possibly helping reduce the death toll from the mosquito-borne disease that kills up to half a million young children a year.
LA ARTEMISA UNA PLANTA IMPORTANTE DE LA FARMACOPEA ORIENTAL, REDESCUBIERTA
El redescubrimiento de la artemisa anual se produjo durante la guerra del Vietnam y, a fecha de hoy, ha contenido mucho la expansión de la peligrosa malaria, causada por un parásito transmitido a través de la picadura de un mosquito. Hoy se sabe, además, que la artemisina que contiene es extraordinaria ante muchas enfermedades.